NASDAQ$AKYA
Akoya Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Akoya Biosciences' second-quarter revenue rebounded with sequential growth, while aligning cost structure with strategic objectives.
Akoya Biosciences reported a 1.5% year-over-year decrease in revenue, totaling $23.2 million for the second quarter of 2024. The company's gross margin increased to 57.8%, and the operating loss decreased to $11.1 million. They are updating the full year 2024 revenue to be in the range of $96-104 million.
- Second-quarter revenue was $23.2 million, a 26.2% increase quarter-over-quarter.
- Gross margin was 57.8%, compared to 51.5% in the second quarter of 2023.
- Operating expenses were $24.5 million, a 22.0% year-over-year decrease.
- Loss from operations was $11.1 million, a 42.4% year-over-year decrease.
Headline financials
Revenue & EPS history
Akoya · Revenue · Quarterly
$23.2M
Revenue by segment
Akoya · $18M total across 1 segment · Q3 2023
- Product revenue$18M+25.3%100.0%
Forward guidance
Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow breakeven by year end. The Company now expects the full year 2024 revenue to be in the range of $96-104 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2024
-3.7%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-17.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+13.7%
Q4 2021
Best reaction
-31.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | +1.0% | +24.8% | +23.8% | |
| Q4 2025 | +3.8% | +9.2% | -30.7% | |
| Q3 2024 | -24.9% | -33.2% | -29.5% | |
| Q2 2024 | -9.5% | -0.9% | +5.5% | |
| Q1 2024 | -31.9% | -35.1% | -50.0% | |
| Q4 2023 | -15.4% | -17.1% | -28.1% | |
| Q3 2023 | +10.0% | +6.9% | +16.4% | |
| Q2 2023 | +0.9% | -6.5% | -23.9% | |
| Q1 2023 | -2.5% | -17.1% | -18.8% | |
| Q4 2022 | -7.3% | -17.2% | -36.6% | |
| Q3 2022 | -15.1% | — | — | |
| Q2 2022 | +5.0% | — | — | |
| Q1 2022 | -11.9% | — | — | |
| Q4 2021 | +13.7% | — | — | |
| Q3 2020 | +1.5% | — | — | |
| Q3 2021 | +0.2% | — | — | |
| Q2 2021 | -0.1% | — | — | |
| Q4 2020 | +9.5% | — | — | |
| Q1 2021 | +2.3% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro